ESR1 and breast carcinoma: Breast cancer is both clinically and molecularly heterogeneous and is, in practice, stratified by hormonal receptors (ER and PR), by HER2 status, and, increasingly, by expression of other biomarkers such as Ki67 or by gene expression profiling methodologies.